3:I[9275,[],""]
5:I[1343,[],""]
6:I[9301,["159","static/chunks/159-dee13bf1387d75f0.js","118","static/chunks/118-b54047542ea39065.js","185","static/chunks/app/layout-a67c2ff64eb7f39d.js"],"MobileNavProvider"]
7:I[1551,["159","static/chunks/159-dee13bf1387d75f0.js","118","static/chunks/118-b54047542ea39065.js","185","static/chunks/app/layout-a67c2ff64eb7f39d.js"],"ModalProvider"]
8:I[4805,["159","static/chunks/159-dee13bf1387d75f0.js","118","static/chunks/118-b54047542ea39065.js","185","static/chunks/app/layout-a67c2ff64eb7f39d.js"],"DropdownProvider"]
9:I[512,["159","static/chunks/159-dee13bf1387d75f0.js","118","static/chunks/118-b54047542ea39065.js","185","static/chunks/app/layout-a67c2ff64eb7f39d.js"],"default"]
b:I[8173,["159","static/chunks/159-dee13bf1387d75f0.js","118","static/chunks/118-b54047542ea39065.js","857","static/chunks/857-650ef115b721dbbb.js","931","static/chunks/app/page-6d21cc1024998357.js"],"Image"]
c:I[231,["159","static/chunks/159-dee13bf1387d75f0.js","118","static/chunks/118-b54047542ea39065.js","857","static/chunks/857-650ef115b721dbbb.js","931","static/chunks/app/page-6d21cc1024998357.js"],""]
d:I[9564,["159","static/chunks/159-dee13bf1387d75f0.js","118","static/chunks/118-b54047542ea39065.js","185","static/chunks/app/layout-a67c2ff64eb7f39d.js"],"default"]
e:I[3656,["159","static/chunks/159-dee13bf1387d75f0.js","118","static/chunks/118-b54047542ea39065.js","185","static/chunks/app/layout-a67c2ff64eb7f39d.js"],"default"]
f:I[179,["159","static/chunks/159-dee13bf1387d75f0.js","118","static/chunks/118-b54047542ea39065.js","185","static/chunks/app/layout-a67c2ff64eb7f39d.js"],"default"]
4:["slug","resources","c"]
0:["PtsZ7C-Mqnfw5TAQM0dr9",[[["",{"children":[["slug","resources","c"],{"children":["__PAGE__?{\"slug\":[\"resources\"]}",{}]}]},"$undefined","$undefined",true],["",{"children":[["slug","resources","c"],{"children":["__PAGE__",{},[["$L1","$L2"],null],null]},["$","$L3",null,{"parallelRouterKey":"children","segmentPath":["children","$4","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L5",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","children":[["$","head",null,{"children":[["$","meta",null,{"name":"theme-color","media":"(prefers-color-scheme: light)","content":"#FFFFFF"}],["$","meta",null,{"name":"theme-color","media":"(prefers-color-scheme: dark)","content":"#1F2937"}],["$","link",null,{"rel":"icon","type":"image/x-icon","href":"/favicon.jpeg"}]]}],["$","body",null,{"className":"__className_c0e2b6 bg-background-light dark:bg-background-dark","children":["$","$L6",null,{"children":["$","$L7",null,{"children":["$","$L8",null,{"children":["$","div",null,{"className":"flex flex-col min-h-screen","children":[["$","$L9",null,{}],["$","main",null,{"className":"flex-grow","children":["$","$L3",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L5",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$La","notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"bg-surface-light dark:bg-surface-dark px-6 lg:px-8 py-8","children":["$","div",null,{"className":"container mx-auto grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-8","children":[["$","div",null,{"className":"w-full flex justify-between items-center lg:col-span-3 md:col-span-2","children":["$","a",null,{"href":"/","className":"text-lg font-semibold text-text-primary-light dark:text-text-primary-dark","children":[["$","$Lb",null,{"src":"/openbench/svg/OpenBenchLogo_Horizontal_Color.svg","alt":"OpenBench","width":144,"height":36,"className":"hidden dark:block"}],["$","$Lb",null,{"src":"/openbench/svg/OpenBenchLogo_Horizontal_Black.svg","alt":"OpenBench","width":144,"height":36,"className":"block dark:hidden"}]]}]}],["$","div",null,{"className":"space-y-2 lg:col-span-2 w-fit","children":[["$","a","Resources",{"href":"/resources","className":"block text-sm text-text-primary-light dark:text-text-primary-dark hover:text-text-secondary-light dark:hover:text-text-secondary-dark","children":"Resources"}],["$","a","About",{"href":"/about","className":"block text-sm text-text-primary-light dark:text-text-primary-dark hover:text-text-secondary-light dark:hover:text-text-secondary-dark","children":"About"}],["$","a","Team",{"href":"/team","className":"block text-sm text-text-primary-light dark:text-text-primary-dark hover:text-text-secondary-light dark:hover:text-text-secondary-dark","children":"Team"}]]}],["$","div",null,{"className":"space-y-2","children":[["$","p",null,{"className":"text-sm text-text-primary-light dark:text-text-primary-dark font-semibold","children":"OpenBench"}],["$","a",null,{"href":"mailto:discovery@opnbnch.com","className":"block text-sm text-text-primary-light dark:text-text-primary-dark underline","children":"discovery@opnbnch.com"}],["$","p",null,{"className":"text-sm text-text-primary-light dark:text-text-primary-dark","children":["535 Mission Street ",["$","br",null,{}]," Floor 14 ",["$","br",null,{}]," San Francisco, CA 94105"]}]]}],["$","div",null,{"className":"space-y-2 lg:col-span-3 md:col-span-2","children":["$","p",null,{"className":"text-sm text-text-primary-light dark:text-text-primary-dark italic","children":"OpenBench is the world’s only fee-for-success contract research organization in drug discovery."}]}],["$","div",null,{"className":"col-span-1 md:col-span-2 lg:col-span-3 text-center mt-8","children":[["$","p",null,{"className":"text-sm text-text-muted-light dark:text-text-muted-dark","children":["© 2025 OpenBench, Inc."," "]}],["$","p",null,{"className":"text-sm text-text-muted-light dark:text-text-muted-dark mt-3","children":["$","$Lc",null,{"href":"/privacy-policy","className":"underline","children":"Privacy Policy"}]}]]}]]}]}],["$","$Ld",null,{}],["$","$Le",null,{}],["$","$Lf",null,{}]]}]}]}]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"https://opnbnch.github.io/_next/static/css/c826dda4b6e58944.css","precedence":"next","crossOrigin":"$undefined"}]],"$L10"]]]]
11:"$Sreact.suspense"
12:I[1481,["159","static/chunks/159-dee13bf1387d75f0.js","118","static/chunks/118-b54047542ea39065.js","857","static/chunks/857-650ef115b721dbbb.js","931","static/chunks/app/page-6d21cc1024998357.js"],"PreloadCss"]
2:["$","$11",null,{"fallback":null,"children":[["$","$L12",null,{"moduleIds":"$undefined"}],"$L13"]}]
a:["$","div",null,{"className":"py-12 px-6 lg:px-8 max-w-3xl mx-auto","children":["$","$11",null,{"fallback":null,"children":[["$","$L12",null,{"moduleIds":["app/not-found.tsx -> @/markdown/404.mdx"]}],"$L14"]}]}]
10:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"Resources | OpenBench"}],["$","meta","3",{"name":"description","content":"OpenBench is the first and only success-driven service for small molecule hit discovery."}],["$","meta","4",{"name":"application-name","content":"OpenBench"}],["$","meta","5",{"name":"robots","content":"index, follow"}],["$","meta","6",{"property":"og:title","content":"Resources"}],["$","meta","7",{"property":"og:description","content":"OpenBench is the first and only success-driven service for small molecule hit discovery."}],["$","meta","8",{"property":"og:site_name","content":"Open Bench"}],["$","meta","9",{"property":"og:locale","content":"en_US"}],["$","meta","10",{"property":"og:image","content":"https://opnbnch.github.io/preview-image-fallback.png"}],["$","meta","11",{"property":"og:image:width","content":"1200"}],["$","meta","12",{"property":"og:image:height","content":"630"}],["$","meta","13",{"property":"og:type","content":"website"}],["$","meta","14",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","15",{"name":"twitter:site","content":"@opnbnch"}],["$","meta","16",{"name":"twitter:creator","content":"@opnbnch"}],["$","meta","17",{"name":"twitter:title","content":"Resources"}],["$","meta","18",{"name":"twitter:description","content":"OpenBench is the first and only success-driven service for small molecule hit discovery."}],["$","meta","19",{"name":"twitter:image","content":"https://opnbnch.github.io/preview-image-fallback.png"}],["$","link","20",{"rel":"icon","href":"/favicon.jpeg"}],["$","meta","21",{"name":"next-size-adjust"}]]
1:null
13:["$","div",null,{"className":"py-12 px-6 lg:px-8 mx-auto","children":[["$","div",null,{"className":"max-w-5xl mx-auto text-center mt-6 mb-12","children":["$","h3",null,{"className":"text-2xl font-medium mb-3 text-text-primary-light dark:text-text-primary-dark","children":"Learn more about what we're doing at OpenBench"}]}],"$L15"]}]
14:[["$","h1",null,{"className":"text-4xl font-bold mb-4 text-text-primary-light dark:text-text-primary-dark","children":"Page Not Found"}],"\n",["$","p",null,{"className":"mb-4 text-text-primary-light dark:text-text-primary-dark","children":["We couldn't find the page you were looking for. ",["$","$Lc",null,{"className":"text-primary-light dark:text-primary-dark underline hover:text-primary-light-hover dark:hover:text-primary-dark-hover","href":"/","children":"Return home"}],"."]}]]
16:I[4398,["159","static/chunks/159-dee13bf1387d75f0.js","118","static/chunks/118-b54047542ea39065.js","857","static/chunks/857-650ef115b721dbbb.js","931","static/chunks/app/page-6d21cc1024998357.js"],"default"]
15:["$","div",null,{"className":"py-4 px-6 lg:px-8 bg-background-light dark:bg-background-dark","children":["$","$L16",null,{"posts":[{"title":"Embracing Results-Driven Discovery","author":"Lewis Martin","date":"2021-06-17","description":"June 2, 2021 marked 10 years since Anthony Nicholls published his sensible, skeptical blog post “Avoiding Hype-based Science,” in which he advised what—and what not—to do when making technology decisions in preclinical drug discovery.","type":"blog","href":"/resources/embracing-results-driven-discovery"},{"title":"858 Therapeutics and OpenBench Launch Small Molecule Drug Discovery Collaboration","description":"SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--858 Therapeutics and OpenBench today announced a collaboration to discover small molecule inhibitors using OpenBench’s structure-based machine learning platform. The collaboration will focus initially on an undisclosed target nominated by 858 Therapeutics. [...]","date":"November 4, 2024","href":"https://www.biospace.com/press-releases/858-therapeutics-and-openbench-launch-small-molecule-drug-discovery-collaboration","type":"press"},{"title":"OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration","description":"SAN FRANCISCO, Sept. 17, 2024 /PRNewswire/ -- OpenBench, Inc., a pioneer in AI-enabled success-driven small molecule discovery partnerships, today announced the launch of a collaboration with ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance. The parties aim to apply OpenBench's success-driven discovery approach and structure-based machine learning platform to enrich early discovery efforts against an undisclosed target identified by ORIC's resistance platform to target cancer-specific vulnerabilities. [...]","date":"September 17, 2024","href":"https://www.prnewswire.com/news-releases/openbench-and-oric-pharmaceuticals-launch-success-driven-discovery-collaboration-302250595.html","type":"press"},{"title":"OpenBench Assigns Leads to OnKure to Advance Pursuit of Precision Oncology Drugs","description":"SAN FRANCISCO, June 3, 2024 /PRNewswire/ -- OpenBench, Inc., a pioneer in AI enabled success-driven small molecule discovery partnerships, today announced that it has assigned a library of promising lead compounds to OnKure, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, to advance OnKure's pursuit of an important precision oncology target. [...]","date":"June 3, 2024","href":"https://www.prnewswire.com/news-releases/openbench-assigns-leads-to-onkure-to-advance-pursuit-of-precision-oncology-drugs-302162132.html","type":"press"},{"title":"OpenBench and Related Sciences Launch Success-Driven Collaboration","description":"SAN FRANCISCO, June 6, 2023 /PRNewswire/ -- OpenBench, Inc., a pioneer in success-driven small molecule discovery collaborations, today announced the launch of a collaboration with Related Sciences (\"RS\"), a data science-driven drug discovery studio, to leverage OpenBench's structure-based machine learning platform to find novel, potent chemical hit material for an initial high value RS target. [...]","date":"June 6, 2023","href":"https://www.prnewswire.com/news-releases/openbench-and-related-sciences-launch-success-driven-collaboration-301843939.html","type":"press"},{"title":"Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery","description":"DURHAM, N.C. and SAN FRANCISCO, April 27, 2023 (GLOBE NEWSWIRE) -- Tavros Therapeutics, Inc., a precision oncology platform company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities, and OpenBench, Inc., a screening platform pioneering success-driven small molecule discovery partnerships, today announced the companies have entered into a collaboration agreement to discover small molecule modulators of up to five oncology targets across an initial 18-month term. [...]","date":"April 27, 2023","href":"https://www.biospace.com/tavros-therapeutics-and-openbench-expand-strategic-collaboration-for-small-molecule-drug-discovery","type":"press"},{"title":"Success-driven hit discovery enabled by success in the synthesis","description":"SAN FRANCISCO and KYIV, UKRAINE, Mar. 6, 2023 -- OpenBench, the first success-driven service for small molecule hit discovery, and Enamine, the world’s leading provider of astronomical numbers of compounds for biological screening, today announced the extension of their collaboration to enrich global early discovery efforts. [...]","date":"March 6, 2023","href":"https://enamine.net/news-press-releases/press-releases/1446-success-driven-hit-discovery-enabled-by-success-in-the-synthesis","type":"press"},{"title":"Carolina collaborating with OpenBench to enhance therapeutic discoveries","description":"CHAPEL HILL, N.C. and SAN FRANCISCO, Nov. 9, 2022 -- The University of North Carolina at Chapel Hill’s Office of the Vice Chancellor for Research (OVCR) and Office of Technology Commercialization (OTC) have partnered with OpenBench, Inc., the first success-driven service for small molecule hit discovery, to advance drug discovery at Carolina. The partnership is focused on high-value oncology targets identified by researchers at the University. [...]","date":"November 9, 2022","href":"https://research.unc.edu/2022/11/09/carolina-collaborating-with-openbench-to-enhance-therapeutic-discoveries/","type":"press"},{"title":"OpenBench Teams Up with Volastra to Discover Early Research Hits","description":"OpenBench enters a collaboration with Volastra Therapeutics to discover small molecule antagonists for cancer treatment.","date":"October 18, 2022","href":"SAN FRANCISCO, Oct. 18, 2022 /PRNewswire/ -- OpenBench, Inc., a pioneer in success-driven small molecule discovery partnerships, today announced that it has entered into a success-driven collaboration with Volastra Therapeutics, Inc., an oncology company focused on exploiting chromosomal instability to treat cancer, in which OpenBench will discover novel, potent small molecule antagonists to enrich Volastra's early discovery efforts against an undisclosed cancer target. [...]","type":"press"},{"title":"OpenBench Assigns Two AI-Discovered Series to HemoShear Therapeutics","description":"SAN FRANCISCO, June 7, 2022 /PRNewswire/ -- OpenBench, Inc., a pioneer in success-driven hit discovery partnerships, has agreed to assign ownership of two promising chemical series to HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, to advance HemoShear's pursuit of an undisclosed rare disease target. [...]","date":"June 7, 2022","href":"https://www.prnewswire.com/news-releases/openbench-assigns-two-ai-discovered-series-to-hemoshear-therapeutics-301562214.html","type":"press"},{"title":"OpenBench and Tavros Therapeutics Announce Collaboration to Pursue First-in-class Cancer Target","description":"DURHAM, N.C. and SAN FRANCISCO, Dec. 2, 2021 /PRNewswire/ -- Tavros Therapeutics, a privately held biotechnology company discovering first-in-class cancer therapies, and OpenBench, an emerging leader in AI-enabled small molecule discovery, today announced a collaboration in which OpenBench will identify novel, potent antagonists against an undisclosed cancer target that was identified by Tavros's proprietary functional genomics platform. [...]","date":"December 2, 2021","href":"https://www.prnewswire.com/news-releases/openbench-and-tavros-therapeutics-announce-collaboration-to-pursue-first-in-class-cancer-target-301435873.html","type":"press"},{"title":"OpenBench and HemoShear Therapeutics Agree to Pursue Rare Disease Target Using Artificial Intelligence","description":"SAN FRANCISCO, Oct. 5, 2021 /PRNewswire/ -- OpenBench, Inc., an emerging leader in AI-enabled small molecule discovery, entered into an agreement with HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, to use the OpenBench virtual screening platform to identify novel, potent inhibitors of an undisclosed rare disease target. [...]","date":"October 5, 2021","href":"https://www.prnewswire.com/news-releases/openbench-and-hemoshear-therapeutics-agree-to-pursue-rare-disease-target-using-artificial-intelligence-301312995.html","type":"press"}]}]}]
